EYPT
EyePoint Pharmaceuticals Inc (EYPT)
Healthcare • NASDAQ • $13.66+1.86%
- Symbol
- EYPT
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $13.66
- Daily Change
- +1.86%
- Market Cap
- $1.15B
- Trailing P/E
- N/A
- Forward P/E
- -4.92
- 52W High
- $19.11
- 52W Low
- $5.30
- Analyst Target
- $37.17
- Dividend Yield
- N/A
- Beta
- 1.77
EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for vascular endothelial growth factor mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E that is in pre-clinical development phase for potentially improve …
Company websiteResearch EYPT on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.